文献速递治疗药物监测与药物基因组学

检测方法为何在模型引导精准给药中至关重要:以克罗恩病乌司奴单抗为例

Why the Assay Matters in Model-Informed Precision Dosing: An Example of Ustekinumab in Crohn's Disease.
PubMed 文献 · Clin Pharmacokinet · 2026-04-08

本研究利用83例克罗恩病患者数据,分别用均相迁移率变动分析和酶联免疫吸附测定检测乌司奴单抗浓度并建立两个群体药动学模型。贝叶斯预测在检测方法与模型匹配时临床可接受,错配则准确性下降。检测偏倚对模型引导精准给药的预测性能有临床相关影响。

要点

  • 均相迁移率变动分析所测乌司奴单抗浓度整体比酶联免疫吸附测定高8.1 mg/L。
  • 检测方法与群体药动学模型匹配时,贝叶斯预测相对偏倚小于20%且95%CI含零。
  • 错配组合降低预测准确性,模型先验平坦化策略仅部分改善但不能完全纠正偏倚。

核心结论

  • 检测偏倚对模型引导精准给药的预测性能有临床相关影响。
  • 应确保治疗药物监测的检测方法与构建群体药动学模型所用检测方法一致,以获得准确且临床可接受的剂量预测。

研究设计与样本

  • 回顾性利用83例克罗恩病患者数据,分别用均相迁移率变动分析和酶联免疫吸附测定检测乌司奴单抗浓度。
  • 基于两种检测方法建立两个对应的群体药动学模型,并在检测数据与模型匹配及错配组合下进行贝叶斯预测。
  • 用相对偏倚和相对均方根误差评估预测准确性及精密度,并预设临床可接受阈值。

主要发现

  • 均相迁移率变动分析所测乌司奴单抗浓度整体比酶联免疫吸附测定高8.1 mg/L(95%CI -23.6, 39.7)。
  • 基于均相迁移率变动分析模型的清除率估计为0.107 L/day(相对标准误7.6%),系统性低于基于酶联免疫吸附测定模型的0.235 L/day(相对标准误5.4%)。
  • 检测数据与群体药动学模型匹配时,贝叶斯预测在所有场景下临床可接受(相对偏倚<20%,95%CI含零)。
  • 错配组合导致准确性下降;无论使用哪个群体药动学模型,均相迁移率变动分析数据的精密度最高。
  • 模型先验平坦化策略改善了部分错配场景的预测性能,但未能完全纠正偏倚。

关键数值与推荐

  • 临床可接受阈值预设为相对偏倚<20%且95%CI含零。
  • 检测方法与群体药动学模型匹配时,贝叶斯预测在所有场景下满足上述临床可接受标准。

临床怎么用

  • 临床开展乌司奴单抗治疗药物监测时,应确认检测方法并与模型引导精准给药所用群体药动学模型的检测方法保持一致。
  • 检测方法与模型错配时,贝叶斯预测准确性下降,应谨慎解读剂量推荐。
  • 模型先验平坦化策略可作为错配时的部分缓解手段,但不能替代检测方法与模型的一致性。

局限性

  • 本研究为回顾性数据再利用,样本为83例克罗恩病患者。
  • 研究仅以乌司奴单抗在克罗恩病中为例,结论外推至其他药物或人群需谨慎。
  • 模型先验平坦化策略未能完全纠正错配带来的偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Systematic bias between therapeutic drug monitoring assays may lead to inappropriate treatment decisions in clinical practice. While such bias is well recognized, its impact on model-informed precision dosing remains unexplored. In this study, we evaluate how assay bias affects the predictive performance of population pharmacokinetic models, using ustekinumab in patients with Crohn's disease as an example. METHODS: We repurposed data from 83 patients with Crohn's disease. Ustekinumab concentrations were measured using both an homogeneous mobility shift assay and enzyme-linked immunosorbent assay. Two corresponding population pharmacokinetic models were developed. Bayesian forecasting was performed under matched and mismatched combinations of assay data and population pharmacokinetic models. Predictive accuracy and precision were assessed using relative bias and relative root mean square error, with predefined thresholds for clinical acceptability. Agreement between assays and clearance estimates was evaluated using Bland-Altman plots, Deming regression, and concordance correlation coefficients. Model prior flattening strategies were explored to mitigate mismatches between model priors and therapeutic drug monitoring data. RESULTS: Ustekinumab concentrations measured by the homogenous mobility shift assay were overall 8.1 mg/L higher than those measured by an enzyme-linked immunosorbent assay (95% confidence interval -23.6, 39.7). Clearance estimates from the homogenous mobility shift assay-based population pharmacokinetic model were systematically lower (0.107 L/day; relative standard error, 7.6%) compared with those from the enzyme-linked immunosorbent assay-based population pharmacokinetic model (0.235 L/day; relative standard error, 5.4%). When assay data and population pharmacokinetic models were matched, Bayesian forecasting yielded clinically acceptable predictions across all scenarios (relative bias <20%, 95% confidence interval including zero). Mismatched combinations led to reduced accuracy. Precision was highest using the homogenous mobility shift assay data, irrespective of the population pharmacokinetic model. Flattening strategies improved predictive performances in some mismatched scenarios but did not fully recover bias. CONCLUSIONS: Assay bias has a clinically relevant impact on the predictive performance of model-informed precision dosing. Our findings underscore the importance of aligning the therapeutic drug monitoring assay format with the assay format used to build the population pharmacokinetic model to ensure accurate and clinically acceptable dosing predictions.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Zhang W, Wang Z, Dervieux T, et al. Why the Assay Matters in Model-Informed Precision Dosing: An Example of Ustekinumab in Crohn's Disease. Clin Pharmacokinet. 2026. PMID: 41951930. doi:10.1007/s40262-026-01639-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。